Reata has active clinical, preclinical, and internal discovery programs in many significant disease areas. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the response to cellular stress in serious and life-threatening diseases that have limited or no approved therapies.
Our lead product candidates, bardoxolone methyl and omaveloxolone, are Nrf2 activators. Nrf2 is a transcription factor that normalizes mitochondrial function, restores redox balance, and resolves inflammation. Bardoxolone methyl is being evaluated in clinical trials for the treatment of several forms of chronic kidney diseases including Alport syndrome, autosomal dominant polycystic kidney disease, IgA nephropathy, type 1 diabetic CKD, and focal segmental glomerulosclerosis. Omaveloxolone is being evaluated in a severe neurologic disorder called Friedreich’s ataxia.
We are developing a novel class of proteins that target pathways involved in the cellular stress response to misfolded proteins and mitochondrial protein import. Our lead product candidate, RTA 901, and related analogs have shown promising effects in animal models of neurological disease. No safety or tolerability issues were observed in the phase 1 clinical trial of RTA 901.
Reata has identified a series of potent and selective RORγt inhibitors that act through a novel allosteric binding mode to block Th17 cell differentiation. Our lead product candidate, RTA 1701, is orally bioavailable and demonstrates significant efficacy in animal models of rheumatoid arthritis and multiple sclerosis.
Partnering and In-Licensing
In addition to internal discovery, we continue to seek additional opportunities to in-license and collaboratively develop novel technologies from premier academic institutions. This operating model of combined internal discovery, in-licensing, and collaborative development guided the founding of Reata, and we continue this strategy today to maintain a pipeline of promising development programs.